Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-02-07

Clinical Trial Update: A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia [Phase 4]

View source ↗

Summary

A Phase 4 postmarketing trial evaluating Xuezhikang Capsule for dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xuezhikang Capsule

Snippet

Sponsor: China Academy of Chinese Medical Sciences | Conditions: Dyslipidemia | Phase 4 | Status: COMPLETED